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ABSTRACT
Protein Kinase C-iota (PKC-ι), an atypical protein kinase C isoform
manifests its potential as an oncogene by targeting various aspects of cancer
cells such as growth, invasion and survival. PKC-ι confers resistance to druginduced apoptosis in cancer cells. The acquisition of drug resistance is a major
obstacle to good prognosis in neuroblastoma. The focus of the dissertation was
three-fold: First to study the role of PKC-ι in the proliferation of neuroblastoma.
Secondly, to identify the efficacy of [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3dihydroxycyclopentyl] methyl dihydrogen phosphate (ICA-1) as a novel PKC-ι
inhibitor in neuroblastoma cell proliferation and apoptosis. Finally, to analyze
whether PKC-ι could self-regulate its expression. Cyclin dependent kinase 7
(Cdk7) phosphorylates cyclin dependent kinases (cdks) and promotes cell
proliferation. Our data shows that PKC-ι is an in-vitro Cdk7 kinase and that
neuroblastoma cells proliferate via a PKC-ι/Cdk7/cdk2 cell signaling pathway.
ICA-1 specifically inhibits the activity of PKC-ι but not that of PKC-zeta (PKC-ζ),
the closely related atypical PKC family member. The IC50 for the kinase activity
assay was approximately 0.1µM which is 1000 times less than that of
aurothiomalate, a known PKC-ι inhibitor. The phosphorylation of Cdk7 by PKC-ι
was potently inhibited by ICA-1. ICA-1 mediates its antiproliferative effects on
neuroblastoma cells by inhibiting the PKC-ι/Cdk7/cdk2 signaling pathway. ICA-1
(0.1µM) inhibited the in-vitro proliferation of BE(2)-C neuroblastoma cells by 58%

vii

(P=0.01). Additionally, ICA-1 also induced apoptosis in neuroblastoma cells.
Interestingly, ICA-1 did not affect the proliferation of normal neuronal cells
suggesting its potential as chemotherapeutic with low toxicity. Hence, our results
emphasize the potential of ICA-1 as a novel PKC-ι inhibitor and
chemotherapeutic agent for neuroblastoma.
Bcr-Abl has been shown to regulate the activation of the transcription
factor ELK-1 which in turn regulates the expression of PKC-ι. Alternatively, we
hypothesize that PKC-ι can self regulate its expression by indirectly regulating
the activity of Elk-1 in an ERK1 dependent manner. Our preliminary data shows
that there was robust increase in the expression as well as association of PKC-ι
and Elk-1 in actively proliferating neuroblastoma cells suggesting a potential role
of PKC-ι in regulating the activity of Elk-1. Analysis of the subcellular fractions
also presented a similar increase in the association between PKC-ι and Elk-1 in
the nuclear fraction of actively proliferating cells as compared to cytoplasm.
Interestingly, the nuclear expression of PKC-ι was also found to be higher in
these cells, suggesting that PKC-ι translocated to the nucleus in actively
proliferating cells and regulated the transcriptional activity of Elk-1. However, our
data from in-vitro kinase activity demonstrated that PKC-ι was not an Elk-1
kinase but that it increased the phosphorylation of Elk-1 in the presence of ERK1,
an upstream kinase of Elk-1 in the Bcr-Abl mediated regulatory pathway of PKCι. This suggested that ERK1 was integral to the self-regulatory activity of PKC-ι.
In conclusion, we hypothesize that the self-regulatory mechanism of PKC-ι is
initiated by the translocation PKC-ι into the nucleus where it activates ERK1.

viii

This promotes the activation of its downstream target Elk-1 which subsequently
upregulates the expression of PKC-ι

ix

CHAPTER 1
PROTEIN KINASE C
1.1 Introduction
Cells are normally subjected to strict regulatory mechanisms that limit cell
division. Protein kinases and protein phosphorylation control the entry and
passage of cells through the cell cycle. Cancer is the outcome of abnormalities
in these mechanisms that lead to unchecked cell division. The protein kinase C
(PKC) family of Ser/Thr kinases is involved in transmembrane signal transduction
pathways triggered by various extra and intracellular stimuli [1]. They were first
discovered in bovine cerebellum by Yasutomi Nishizuka and colleagues in the
1970s at Kobe University, Japan [2]. They are involved in the control of various
cellular responses like proliferation, migration, apoptosis and survival of cells [35]. The name PKC was coined by Nishizuka and coworkers as this enzyme was
found to be activated by the Ca2+ dependent protease, Calpain [6]. Research
following this has shown that PKCs not only require calcium for its activation but
also co-factors like the lipid metabolite diacylglycerol (DAG) and
phosphotidylserine (PS) [7-9].
1.2 PKC isozymes
The PKC family consists of thirteen isozymes that can be classified into
different groups on the basis of their co-factor requirements [10, 11]. Group I is
the conventional PKCs (cPKC) which includes the isoforms alpha (α), beta I (βI),
1

beta II (βII) and gamma (γ). They are also called classical isozymes as they are
dependent on calcium, DAG and phospholipids for their activation. Group II is
the novel PKCs (nPKC) and is comprised of delta (δ), epsilon (ε), eta (η) and
theta (θ). They are termed novel because they are calcium independent but
dependent on DAG and phospholipids. The atypical PKC isozymes form the
third group, so called because of their independence of calcium and DAG for
their activation. This group includes PKC zeta (ζ) and PKC iota (ι) in humans/
lambda (λ) in mouse. An additional family member, Protein Kinase D, mu (μ) is
introduced into the PKC family and is sometimes also referred to as an atypical
isozymes [12]. Another distant related family member includes PKC-related
kinases (PRK 1-3), known as PKN [13]
1.3 Structure of Protein kinase C
Protein kinase C family members have highly conserved carboxyl-terminal
catalytic domain. It is due to the structural similarity in the catalytic domain (also
known as the kinase domain), that all PKC isozymes fall under one parent family.
All the PKC isozymes differ from each other on the basis of their amino-terminal
regulatory domain. This domain is important for secondary messenger binding,
recruiting the enzyme to the membrane and protein-protein interactions [7]. The
first isozymes cloned were shown to possess four conserved sequences (C1C4), five variable sequences (V1-V5) and a pseudosubstrate region [14, 15].
The regulatory and the kinase domain are linked to each other by a hinge region
(V3) which is sensitive to cleavage by proteases. (Figure. 1).
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1.3.1 The regulatory domain: The pseudosubstrate domain is located at
the N-terminal adjacent to the C1 domain. This region has a peptide-sequence
similar to that of a substrate but lacks alanine in the phospho-acceptor position.
In the inactive form of PKCs, the pseudosubstrate prevents complete activation
of PKC by blocking the substrate binding pocket [16, 17]. The pseudosubstrate
is released from kinase domain, following the activation of PKCs [18, 19].
The C1 domain is the membrane binding domain common in all the PKC
family members [20]. cPKCs and nPKCs are comprised of two tandem repeats
of cysteine-rich sequence termed as C1A and C1B respectively [21]. They are
involved in the binding of secondary lipid messenger diacylglycerol and phorbol
esters as well as membrane lipids [22, 23]. Atypical PKCs have only one
cysteine rich C1 domain. They lack the DAG and phorbol ester binding residues
[20].
The C2 domain in cPKCs promotes their binding to anionic phospholipids
in a Ca2+-dependent manner [24, 25]. nPKCs have a C2-like domain incapable
of binding to Ca2+ due to absence of essential residues [26, 27]. However, the
C2-like domain assists in protein-protein interactions. A similar mechanism is
also observed in PRKs [13, 28]. aPKCs lack the C2 domain but comprise of an
additional PB1 domain which is known to function in protein-protein interaction
[29].
1.3.2 The catalytic domain: The catalytic domain is 40% homologous to
the kinase domain of protein kinase A (PKA) and protein kinase B (AKT). C3 and
C4 motifs form the conserved sequences in this kinase core. C3 domain
3

comprises the ATP binding site and C4 possesses the substrate binding
sequence responsible for signal transduction [30].
1.4 Protein kinase C regulation
There are several important mechanisms that regulate complete
maturation and activation of PKCs. Primarily, the protein is phosphorylated at
specific residues which release PKCs to the cytosol rendering it catalytically
competent. This initiates the translocation of the protein to the membrane in the
presence of second messengers DAG, Ca2+, PS and phorbol esters. This is then
followed by removal of pseudosubstrate exposing the substrate binding pocket.
1.4.1 Regulation by Phosphorylation: The activation of PKC involves a
cascade of three synchronized phosphorylations [31, 32] (Figure 2.2). The first
step is phosphorylation at the activation loop triggered by phosphoinositidedependent kinase -1 (PDK-1) that is upstream of PKC [33-38]. Phosphorylation
at the activation domain rapidly initiates a chain reaction that involves
autophosphorylation at the turn motif that further promotes the
autophosphorylation at hydrophobic motif [34, 39]. The autophosphorylation at
the turn motif is important in the maturation of PKC. It protects the catalytically
activated form of PKCs from thermal degradation as well as proteolysis [40, 41].
Apart from being responsible for PKC activation, the turn motif is also important
for protein-protein interaction as well as for initiating the mechanism of docking
the enzyme to the membrane. The autophosphorylation at hydrophobic motif
[34, 39] marks the third and final step towards complete maturation of protein
kinase C. This serves to stabilize the protein from proteolytic degradation [42].
4

1.4.2 Regulation by secondary lipid messengers: Once phosphorylated,
PKC is localized to the cytosol but is still inactive due to the presence of
pseudosubstrate at its substrate binding pocket. Upon extracellular stimulation,
phospholipase C stimulates the breakdown of phosphatidylinositol into
phosphatidylinositol 3- kinase (PI3k) and DAG followed by release of Ca2+fom
the internal stores. Ca2+ then binds to the C2 domain of cPKC inducing partial
interaction with anionic phospholipids at the membrane. This induces the protein
to bind DAG via its C1 domain. This high affinity interaction causes
conformational changes in the protein, releasing the auto-inhibitory
pseudosubstrate [43]. nPKCs do not have the Ca2+ binding C2 domain and
hence depend on its C1 domain (particularly C1B) to build its strong interaction
with the membrane. aPKCs on the other hand do not respond to either DAG or
Ca2+.
1.4.3 Regulation by anchoring proteins: The distribution and localization of
PKCs also regulate their overall biological functioning. Proteins from the family
of RACKs (receptors for activated C- kinase) bind different PKCs helping in their
correct cellular localization and also increase their catalytic activity [44]. Another
group of proteins called STICKs (substrates that interact with C-kinase) interact
with immature,
phosphorylated PKC bringing it close to PKC cofactors and release it when
phosphorylated [45].

5

Figure 1.1 Structure of Protein Kinase C. The PKCs have highly conserved Cterminal catalytic domain. The three autophosphorylation sites are activation
loop (A), turn motif (T) and hydrophobic motif (H). The PKCs differ in the
regulatory domains. Conventional PKCs have C2 (Ca2+-binding domain), C1A
(DAG-binding) domain, C1B (PS-binding) domain. The novel PKCs have Cdomain similar to conventional PKCS. The C2 domain is modified and incapable
of binding to Ca2+, thus called C2-like. The C1 domain of atypical PKCs bind to
only PS. Instead of the C2 domain, they have the PB1 domain that is involved in
protein-protein interaction. All PKCs have a pseudosubstrate domain in next to
the N-terminal end. Adapted from [46].
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1.4.4 Protein kinase C Deregulation: Activation of protein kinase C is
followed by its deactivation step. Binding of co-factors to PKCs at membrane
makes them catalytically competent. PKCs undergo conformational change
removing the pseudosubstrate. Association of DAG to PKC is transient. At this
point, the protein due to its open confirmation becomes highly sensitive to
proteases like calpain and dephosphorylation by phosphatases like PP2A [47].
Ultimately, protein kinase C is subjected to degradation via ubiquitin-proteosome
pathway [48, 49].

7

Figure 1.2 Activation of PKCs. The first step in the activation of PKCs is the
phosphorylating of activation loop (A) by PDK-1 at the C-terminal. This triggers
the rapid autophosphorylations at the turn motif (T) and hydrophobic motif (H),
respectively. This promotes the release of the PKC into the cytosol where it is
maintained in the inactive form by binding of the pseudosubstrate (PS) to the
substrate binding domain. The subsequent steps in the activation of PKCs are
triggered by signals that promote the lipid hydrolysis from the membrane and
release cofactors such as Ca2+ and DAG. These events promote the
translocation of the PKCs to the membrane where the co-factors bind to the
regulatory domains of PKCs. Ca2+ binds to the C2 domain (orange) and DAG
binds to C1 domain (blue). The binding of the co-factors generate the energy
required to release the pseudosubstrate form the substrate binding site and
promote the downstream signaling. Adapted from [46]
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CHAPTER 2
ROLE OF PKC-ι IN NEUROBLASTOMA
2.1 Introduction
Neuroblastoma is the most common extra-cranial tumor diagnosed in
children. Its origin lays in the sympathetic nervous system, that is, the network of
nerves transmitting neuronal messages originating in the brain to the various
parts of the body. These highly lethal tumors comprise approximately 10% of all
childhood cancers with a fatality rate of more than 15% [50]. As per the statistics
of the American Cancer Society, approximately 650 new cases of neuroblastoma
are diagnosed each year in the United States. Spontaneous regression of the
tumor or maturity into a benign ganglioneuroma is a characteristic feature of this
cancer [51]. The etiology of this disease hitherto remains obscure. The intensity
of neuroblastoma lies in its primary target, infants and small children.

The

prognosis in case of infants is much better as compared to children over a year.
In the latter case, metastasis is often observed at the time of diagnosis and the
subsequent recovery of the patient is rare [52]. Despite significant educational
efforts, improved diagnostic techniques, and rigorous therapies, neuroblastoma
control remains static. Thus, justifying the importance of increased research to
find a potential cure for this disease.
The distribution of neuroblastoma is represented by Figure 2.1.
primary site of neuroblastoma occurrence is the adrenal gland [53].
9

The

Figure 2.1A Distribution of neuroblastoma in patients <1 year. The chart
represents the distribution of neuroblastoma by primary site in patients <1 years
at diagnosis, among all races and both sexes. Adapted from [53].
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Figure 2.1B Distribution of neuroblastoma in patients >1year. The chart
represents the distribution of neuroblastoma by primary site in patients >1 years
at diagnosis, among all races and both sexes. Adapted from [53].
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The diagnosis, staging and treatment of neuroblastoma have been
explained based on the International criteria for neuroblastoma diagnosis,
staging and treatment [54, 55].
2.1.1 Diagnosis
•

X-rays

•

Bone scans

•

Computerized tomography (CT) scans

•

Magnetic resonance imaging (MRI) scans

2.1.2 Staging: Stage I represents tumor that is localized. It can be totally
removed with surgery. The symptoms of this stage are that the tumor is confined
within a particular body compartment such as abdomen, pelvis or neck.
Stage IIA represents a tumor which is still localized. However, the surgical
removal is not very easy. The symptoms are identical to Stage I.
Stage IIB is where the tumor remains localized similar to Stage IIA and the
surgical removal of tumor is not easy. A major difference in Stage IIA and IIB is
that in the latter, nearby lymph nodes show signs of tumor.
Stage III represents an advanced stage. By this time the surgical removal
of the tumor is not possible. Lymph nodes may or may not contain cancer cells.
The tumor might have begun to metastasize.
Stage IV is represented by metastasis.
Stage IVS is a specialized stage associated with infants <1 year old.
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Patients with this stage have a good chance of recovery. Surprisingly, at this
stage, neuroblastoma sometimes goes away on its own and may not require
treatment.
2.1.3 Treatment: Surgery is usually the first choice of treatment; however,
it is dependent on the location. In case where the tumor is found to be attached
to nearby vital organs like the lungs or the spinal cord, then surgery is considered
too risky.
Chemotherapy is the treatment option when surgery is risky.
This may be used to promote the shrinking of the tumor to facilitate the surgical
removal. This treatment modality is generally used before surgery and before
bone marrow stem cell transplant.
Radiation therapy is used in the event of failure of surgery and
chemotherapy, the next course of action is radiation therapy. High-risk
neuroblastoma patients may receive radiation therapy after chemotherapy and
surgery to prevent cancer from recurring.
Stem cell transplant is primarily used to replenish healthy cells. This is
accompanied by high doses of chemotherapy to kill any remaining cancer cells.
2.1.4 PKC-iota: PKC-ι was first identified in insulin-secreting rat cells
RINm5F by Selbie et al. in 1993 [56]. It is 72% homologous to the other atypical
family member PKC-ζ. However, it is less than 54% homologous to other PKC
isoforms [56]. The role of PKC in carcinogenesis came into the limelight with the
discovery of PKC as a receptor for the tumor-promoting phorbol esters in the
early 1980s [9, 57]. However, PKC-ι is the only PKC isoform that has been
13

successfully proven to be an oncogene [58, 59]. Among the PKCs, PKC-ι is the
most common genomic amplicon as identified by comparative genomic
hybridization [60]. The expression of PKC-ι has been reported to be elevated in
many cancers such as lung [61], pancreas [62], gastric [63], esophagus [64],
hepatocyte [65], breast [66], ovarian [67-69], prostate [70] and brain [71]. It
promotes cell survival in non small cell lung cancer [72] and prostate cancer [73].
PKC-ι has been known to induce resistance to drug mediated apoptosis in
chronic myelogenous leukemia cells [74].
PKCs have been shown to promote multi-drug resistance in
neuroblastoma cells which has been a potent problem in the prognosis of
neuroblastoma [75, 76]. Work from our lab has shown the importance of PKC-ι
in glioma [71] and prostate cancer [73], thus, we were interested in analyzing the
role of PKC-ι in neuroblastoma.
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Figure 2.2 Significance of PKC-ι as an oncogene. Adapted from [59, 77]. The
significance of PKC-ι lies in the fact that it can mediate numerous oncogenic
signaling mechanisms in cells that promote invasion, proliferation and cell
survival. PKC-ι can be activated by a plethora of upstream targets such as
dietary fats, EGF (epidermal growth factor), smoke carcinogens, Bcr-Abl and
Ras.
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2.2 Results
2.2.1 PKC-ι is overexpressed in neuroblastoma tissues: In order to
analyze the role of PKC-ι in neuroblastoma we first determined the expression of
PKC-ι in neuroblastoma tissues. Our preliminary work performed on
neuroblastoma tissues showed a 2.5-fold increase in PKC-ι in adrenal
neuroblastoma compared to normal adrenal biopsies (P = 0.003, Figure 2.3 A,
B). β-actin loading controls demonstrated that approximately equal amounts of
protein were loaded onto the SDS-PAGE.
2.2.2. PKC-ι is overexpressed in actively proliferating neuroblastoma cells:
Furthermore, we tested the expression of PKC-ι in proliferating BE(2)-C cells.
The PKC-ι expression levels were higher in 50% confluent cells (actively
proliferating) than 100% confluent cells (contact inhibited and serum starved).
Additionally, the expression of PKC-ζ, a closely related member of the atypical
PKC family was analyzed. There was no change in the expression of PKC-ζ in
response to contact inhibition. Caspase-3 expression levels were analysed to
ensure that the decrease in the expression of PKC-ι was not an outcome of cells
undergoing apoptosis (Figure 2.3 C, D). These results suggest a potential role of
PKC-ι in the proliferation of BE(2)-C cells.
2.2.3. Proliferation of neuroblastoma cells is PKC-ι dependent: The
potential role of PKC-ι in the proliferation in BE(2)-C cells was confirmed via gene
silencing using PKC-ι siRNA. PKC-ι siRNA (150 nM) significantly reduced the
cell proliferation by 53% at 48 hours (P=0.002) and by 65% at 72 hours
(P<0.001) (Figure 2.3 E). The expression of levels of PKC-ι was also reduces
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significantly (P=0.04) (Figure 2.3F). Expression levels of PKC-ζ remained
invariant (Figure 2.3F). These results indicate that PKC-ι plays an important role
in the proliferation of neuroblastoma cells.
2.3. Summary
Previous work from our laboratory has found that PKC-ι is overexpressed
in actively proliferating prostate cancer and glioma cells [71, 73]. Similarly, we
found higher expression of PKC-ι in adrenal neuroblastoma tissue as well as
neuroblastoma cells suggesting the involvement of PKC-ι in the proliferation of
neuroblastoma cells. Our data suggests that PKC-ι is involved in the proliferation
of neuroblastoma cells. Therefore, it is of interest to analyze whether there is a
PKC-ι mediated proliferation pathway in neuroblastoma.
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Figure 2.3 A, B. PKC-ι is overexpressed in neuroblastoma tissues. (A) Normal
and adrenal neuroblastoma tissue biopsies (60µg) were subjected to SDS-PAGE
and Western blotting was performed with monoclonal antibodies against PKC-ι.
(B) Densitometric analysis of representative immunoblots from 11 normal adrenal
specimens and 11 adrenal malignant neuroblastomas are shown.
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Figure 2.3 C, D PKC-ι is overexpressed in neuroblastoma cells. (C) Endogenous
levels of PKC-ι in BE(2)-C cells were determined by Western blot analysis and
quantified using densitometry, respectively. Equal amounts of cellular proteins
(100µg) from actively proliferating (50%) and contact inhibited (100% S) cells
were loaded in each well and immunoblotted for PKC-ι or PKC-ζ. Caspase-3
was analyzed to ensure that the effect on the levels of proteins was not due to
apoptosis. β-actin levels were analyzed as a loading control (D) Represents
densitometry for the expression of PKC-ι in BE(2)-C cells.
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Figure 2.3 E, F Effect of PKC-ι knockdown. BE(2)-C cells were treated with PKC-ι
siRNA (150nM) for 24-72 hours as described in Materials and Methods. At the
indicated time points, viable cells were counted using Trypan blue exclusion
assay. The data represents n=3 independent experiments (E). The same
population of cells treated with either control siRNA or PKC-ι siRNA was
immunoblotted for PKC-ι. The levels of PKC-ζ were analyzed to determine the
specificity of PKC-ι siRNA. β-actin levels were analyzed as a loading control.
Western blot represents N=3 independent experiments (F).
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CHAPTER 3
NEUROBLASTOMA CELLS PROLIFERATE VIA PKC-ι/Cdk7/cdk2
PROLIFERATION PATHWAY
3.1 Introduction
Cyclin dependent kinases (cdks) are serine/threonine protein kinases that
are mainly involved in regulation of the cell cycle. The Cdk family is comprised of
the following members:
Cdk1 binds to cyclin A to form the M-phase promoting factor (MPF) and
initiates mitosis [78]. Cdk1/cyclin A complex may also play a role in preparation
of the cells for mitosis [79].
Cdk2 coordinates the transition from Gap1 phase to DNA synthesis phase
(G1→S). Cdk2/cyclin E complex triggers the initiation of DNA synthesis at the
commencement of S-phase [78]
Interactions of Cdk1 and Cdk2 with cyclin B have been reported in G2 and
M-phase of the cell cycle [80].
CDK3 is closely related to Cdc2 and Cdk2 and has been reported to play
a role in progression through Gap1 phase [81-83].
Cdk4/cyclin D complex promotes the progression through the Gap1-phase.
They regulate the cell cycle by suppressing the action of pRb protein. [84, 85].
Cdk5 is required during post-mitotic stages of neural differentiation [86,
87].
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Cdk6/cylin D complex promotes progression through the Gap1phase.
They regulate the cell cycle by suppressing the action of pRb protein.
Cdk4 and Cdk6 are termed as secondary Cdks since the cell cycle is not
inhibited in the absence of these proteins [84, 85].
Cdk7 is involved in the regulation of the activity of the cdks. It is part of
CAK (Cyclin dependent kinase activating kinase) complex [78, 88]. The only
CAK identified in eukaryotes is Cdk7 [89].
Cdk8/cyclin C complex is involved in transcription by virtue of their
association wih RNA polymerase II [90-93].
Cdk9/cyclin T complex is involved in transcription [94].
3.1.1 Regulation of Cdks: The activation of cdks requires binding to cyclin
as well as phosphorylation at conserved T residue by CAK [95, 96]. CAK is a
trimeric complex composed of Cdk7, cyclin H and MAT1 [97-101]. CDK7 plays a
dual role; first as CAK, it phosphorylates CDKs to promote cell-cycle and second
as a component of the transcription factor TFIIH, it phosphorylates the C terminal
domain (CTD) of Pol II [95]. Cdk7 regulates the cell-cycle by acting as an
upstream regulator promoting a conformational change that enhances the activity
of target cdks [102]. As part of the transcription machinery, CDK7 acts as a
downstream effector kinase [103]. At mitosis, xeroderma pigmentosum disorder
group D (XPD) promotes the sequestration of CAK from TFIIH releasing the
trimetric CAK to act as a cell-cycle promoter [104]. The activation of Cdk7 is
dependent on phosphorylation at two conserved sites. Phosphorylation at T170

22

on the T-loop induces stable dimerization with cyclin H while phosphorylation at
S164 on the activation loop promotes stabilization of CAK complex [105].
Deactivation of cdks is mediated by Cdk inhibitory subunits (CKIs) or
regulatory kinases that phosphorylate the cdk subunit at inhibitory sites near the
N terminus [106, 107]. CKIs can be divided into two main families:
Cip/Kip forms the first group. It includes p21, p27, and p57: They inhibit
cdk2- and cdk4/6-cyclin complexes involved in G1 and G1/S control.
Ink4 family consists p15, p16, p18, and p19: They specifically inhibit cdk4
and cdk6-cyclin D complexes.
Thus, CKIs proteins are important in regulating the cell-cycle in response
to unfavorable environmental conditions or intracellular signals such as DNA
damage [108, 109].
Previous work in our laboratory demonstrated crosstalk between PKC-ι
and Cdk7 in the regulation of the glioma cell cycle and prostate cancer cell
proliferation [73, 110].
From chapter 2 (Figure 2.3), we observed that PKC-ι is involved in the
proliferation of neuroblastoma cells, therefore, we investigated whether the
proliferation is via PKC-ι/Cdk7 pathway.
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Figure 3.1 Cdks in cell-cycle. The figure represents major Cdks that participate in
progression of cell cycle [78].
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3.2 Results:
3.2.1 Cdk7 is a substrate for PKC-ι: Since, previous work from our
laboratory demonstrated crosstalk between PKC-ι and Cdk7 [73, 110], we first
determined the role of PKC-ι as an in-vitro kinase of Cdk7. Recombinant PKC-ι
was incubated with recombinant Cdk7 in an in-vitro kinase activity assay as
described under Materials and Methods. The data demonstrated that
recombinant PKC-ι directly phosphorylated Cdk7 at T170 (Figure 3.2). A 60%
increase in the phosphorylation of Cdk7 was observed (P=0.02).
3.2.2 BE(2)-C cells proliferate via the PKC-ι/Cdk7/cdk2 pathway: Next, we
investigated whether PKC-ι plays a proliferative role in neuroblastoma through
the Cdk7 pathway as shown in previous studies [110]. Our results show that
PKC-ι directly associated with the phosphorylated forms of both Cdk7 (T170) and
its downstream target cdk2 (T160) (Figure 3.3 A). There was a significant
increase in the levels of pCdk7 in co-immunoprecipitated (both PKC-ι and Cdk7)
samples compared to individual immunoprecipitation. When compared with PKCι alone, the increase was 37% (P= 0.05) and with immunoprecipitation of Cdk7
alone it was 38% (P=0.001). The subsequent increase in the levels of pcdk2
(T160) in co-immunoprecipitation samples were found to be 65% higher
compared to immunoprecipitation of PKC-ι alone (P=0.01) and 37% for Cdk7
(P=0.001). These results suggest that Cdk7 may be a direct downstream
substrate for PKC-ι in BE(2)-C cells. To further analyze the role of PKC-ι as an
in-vitro kinase of Cdk7, recombinant PKC-ι was incubated with
immunoprecipitated Cdk7 in an in-vitro kinase activity assay as described
25

previously. Recombinant PKC-ι directly phosphorylated Cdk7 at T170 (Figure
3.3 B). A 70% increase in the phosphorylation of Cdk7 was observed (P=0.02).
The property of PKC-ι to directly phosphorylate Cdk7 in BE(2)-C cells was
confirmed by gene silencing using PKC-ι siRNA. Immunoblotting for pCdk7
displayed that knockdown of PKC-ι by RNA interference lead to a 60% reduction
in the phosphorylation of Cdk7 (P=0.03) (Figure 3.3 C). These results suggest
that the proliferation of the neuroblastoma cells maybe mediated by the crosstalk
between PKC-ι and Cdk7.

Figure 3.2 PKC-ι directly phosphorylates. Cdk7 (A) Active PKC-ι (0.5μg) and
active Cdk7 (0.5μg) were subjected to an in-vitro kinase activity assay. The
proteins were then separated by SDS-PAGE and Western blotted to determine
the phosphorylation of Cdk7 at T170 and levels of pan-Cdk7. Data represents
N=3 independent experiments.
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Figure 3.3 A, B BE(2)-C cells proliferate via the PKC-ι/Cdk7/cdk2 pathway. (A,
B) Column 1 represents negative controls (-). The first negative control contains
whole cell lysates (200μg) plus rabbit IgG whole molecule (50μl of 1:1 v/v) while
the second negative control was comprised of whole cell lysates (200μg) plus
rabbit IgG whole molecule (50μl) and normal rabbit IgG serum (5μg). (A) PKC-ι
and Cdk7 were immunoprecipitated separately as well as co-immunoprecipitated
from whole cell extracts (200μg) using specific antibodies. Western blot analysis
was performed to determine pCdk7 at T170, pcdk2 at T160, pan-Cdk7, pan-cdk2
and β-actin. (B) Cdk7 (5μg) was immunoprecipitated from whole cell extracts
(200μg), then subjected to an in-vitro kinase activity assay in the presence and
absence of recombinant PKC-ι (0.5μg). The proteins were then separated by
SDS-PAGE and Western blotted to determine the phosphorylation of Cdk7 at
T170 and levels of pan-Cdk7.
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Figure 3.3 C. PKC-ι knockdown inhibits the PKC-ι/Cdk7/cdk2 pathway. Column
1 represents negative controls (-). The first negative control contains whole cell
lysates (200μg) plus rabbit IgG whole molecule (50μl of 1:1 v/v) while the second
negative control was comprised of whole cell lysates (200μg) plus rabbit IgG
whole molecule (50μl) and normal rabbit IgG serum (5μg). Sub-confluent cells
were treated with the siRNA complex (150nM) for 24 hours. Subsequently, Cdk7
was immunoprecipitated and the levels of pCdk7 and pan-Cdk7 in PKC-ι siRNA
(PKC-ι) treated samples were compared with that of control siRNA (C) treated
samples by Western blot analysis. Data represents N=3 independent
experiments.
3.3 Summary
Our data from in-vitro kinase activity assay demonstrates that PKC-ι is an
in-vitro Cdk7 kinase. Immunoprecipitation studies suggests that there is
crosstalk between PKC-ι and Cdk7 in neuroblastoma cell line BE(2)-C cells and
that the cells might be proliferating by the PKC-ι/Cdk7/cdk2 pathway. The
involvement of PKC-ι in the proliferation was confirmed via PKC-ι knockdown
using siRNA which inhibited the phosphorylation of Cdk7. Therefore, our data
suggests that neuroblastoma cells proliferate via PKC-ι/Cdk7/cdk2 pathway.
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CHAPTER 4
ICA-1, A NOVEL PKC-ι INHIBITOR
4.1 Introduction
ICA-1 is a novel PKC-ι inhibitor. ICA-1 is the abbreviation for [4-(5-amino4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl] methyl dihydrogen
phosphate. PKC-ι is the only PKC isoform that has been proven to be an
oncogene [58, 59] PKC-ι mediates numerous signaling pathways that promote
carcinogenesis (Figure 2.2). It promotes cell survival in prostate cancer [73] and
and drug resistance in chronic myelogenous leukemia cells [74]. However, there
has been limited success in developing PKC-ι inhibitors. Furthermore, PKC-ι and
PKC-ζ are 84% homologous with respect to the amino acid sequences of their
catalytic domain. This sequence homology is a major hindrance in successfully
designing an inhibitor that is specific to only PKC-ι and shall not inhibit PKC-ζ.
Aurothiomalate (ATM) is only one FDA approved PKC-ι inhibitor [111] , certifying
the need to develop more potent PKC-ι inhibitors. ATM binds to the the PB1
domain of PKC-ι and inhibits the protein-protein interaction of PKC and its
downstream target. However, since PKC-ι and PKC-ζ have highly conserved
PB1 domain, ATM could induce non-specific inhibition of PKC-ζ. ICA-1, was
designed to bind to the unique sequence of amino acids (469-475) since, both
PKC-ι and PKC-ζ exhibited heterogeneity in this particular sequence [56].
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In the current study, we demonstrated that ICA-1 specifically targets the
activity of PKC-ι with an IC50 of 10 nM in-vitro; however, it did not inhibit the
activity of PKC-ζ. Comparative study of the effect of ATM on the activity of PKC-ι
versus PKC-ζ showed that ATM inhibited the activity of both the isozymes.
Therefore, our data supports the potential of ICA-1 as a novel chemotherapeutic
agent for cancer research.
4.2 Results
4.2.1 Binding of ICA-1 to a sequence of amino acids in the catalytic
domain of PKC-ι: To establish the therapeutic potential of PKC-ι as a drug target
we screened compounds that would bind to a unique sequence in the catalytic
domain of PKC-ι and inhibit its activity. The sequence targeted comprised amino
acid residues 469-475 (glutamine, isoleucine, arginine, isoleucine, proline,
arginine and serine). Molecular docking demonstrated the binding of ICA-1
(Figure 4.1 A) to this sequence (Figure 4.1 B).
4.2.2 ICA-1 specifically inhibits the activity of PKC-ι: Since, PKC-ι and
PKC-ζ are 84% homologous with respect to the amino acid sequences of their
catalytic domain [56], our primary focus was to determine the specificity of ICA-1
by performing a kinase activity assay to analyze the effects of ICA-1 on the
activity of PKC-ι and PKC-ζ. Recombinant active PKC-ι or PKC-ζ, was incubated
with MBP (myelin basic protein), a known substrate for PKCs [112], in the
presence or absence of ICA-1. ICA-1 significantly inhibited the activity of PKC-ι
by 16% at 0.1 µM (P= 0.03), 25% at 1 µM (P<0.05) and 45% at 5μM (P<0.002)
(Figure 4.2 A). However, ICA-1 did not have any significant effect on the activity
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of PKC-ζ (Figure 4.2 C). Furthermore, we made a comparative study between
the specificity of ICA-1 and ATM for PKC-ι and PKC-ζ using a PKC activity assay
kit. ICA-1 significantly decreased the activity of PKC-ι (Figure 4.3 A) by 22.6% at
0.1 µM (P=0.01), 53.47% at 1 µM (P=0.006) and 80% at 5 µM (P=0.002) but not
PKC-ζ (Figure 4.3 B) demonstrating the selectivity of ICA-1 for PKC-ι and not
PKC-ζ. However, ATM at 100µM inhibited the activity of both PKC-ι by 67%
(P=0.02) and PKC-ζ by 55 % (P=0.01) (Figure 4.3 C, D). Lower concentrations
of ATM had no significant effect on the activity of either of the enzymes. The
ICA-1 induced phosphotransferase inhibition was tested using a more sensitive
γ-32P ATP method. The IC50 obtained was approximately 10 nM (P=0.01) (Figure
4.4). Collectively, these results show that ICA-1 is a specific PKC-ι inhibitor.
4.2.3 ICA-1 is a competitive inhibitor of PKC-ι: To test whether the
inhibitory effect of ICA-1 on the activity of PKC-ι is competitive or noncompetitive, we analyzed the effect of ICA-1 by varying the concentration of MBP
(0.0025mg/ml - 0.02 mg/ml). Data from the Lineweaver- burke plot (Figure 4.5)
show that the inhibitory effects of ICA-1 was inversely proportional to the
substrate concentration suggesting that ICA-1 is a competitive inhibitor of PKC-ι.
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Figure 4.1 Chemical structure and Molecular Docking of ICA-1. (A) The structure
of ICA-1 [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl]methyl
dihydrogen phosphate. It has a molecular weight of 336.18 g/mol and is soluble
in water. (B) Molecular docking of ICA-1 on amino acid residues 469 - 475 of the
catalytic domain of PKC-ι.
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Figure 4.2 A, B, C, D. ICA-1 specifically inhibits the activity of PKC-ι.

33

Figure 4.2 A, B, C, D. ICA-1 specifically inhibits the activity of PKC-ι.
Recombinant active PKC-ι (A) or PKC-ζ (C) (0.01µg/µl) was incubated with
myelin basic protein (5μg) in the presence or absence of ICA-1 (0.1μM, 1µM and
5μM) in a kinase activity assay. (A, C) Show the Western blot analysis for the
effect of ICA-1 on the activities of PKC-ι and PKC-ζ respectively. Western blots
represents N=3 independent experiments. (B, D) represent the densitometry for
effect of PKC-ι and PKC-ζ activity respectively, upon ICA-1 treatment.
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Figure.4.3 A, B, C, D. Comparison between ICA-1 and ATM. Recombinant PKCι or PKC-ζ (0.01μg/μl) was treated with different concentrations of ICA-1 (A, B) or
ATM (C, D) for 10 min at 4°C followed by incubation with phosphatidylserine and
ATP for 30 min at 30°C. Data represents N=3 independent experiments.

35

Figure 4.4 IC50 of ICA-1. Recombinant PKC-ι (0.01µg) was treated with different
concentrations of ICA-1 for 10 min at 4°C followed by incubation with PIP3 for 10
min at 30°C. Data represents N=2 independent experiments.
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Figure 4.5 Competitive inhibition of PKC-ι activity by ICA-1. Recombinant active
PKC-ι (0.01μg/μl) was incubated with varying concentrations of MBP (0.0025
mg/ml, 0.05 mg/ml, 0.010 mg/ml and 0.02 mg/ml) in the presence or absence of
ICA-1 (1 µM) followed by detection by ELISA based assay. Data represents N=3
independent experiments.
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4.3 Summary
ICA-1 specifically inhibits the activity of PKC-ι and did not have any
significant effect on activity of PKC-ζ. Comparison with the FDA-approved PKC-ι
inhibitor, ATM showed that ICA-1 is a more potent and specific PKC-ι inhibitor.
The inhibitory action of ICA-1 is competitive. This is very important since, it
suggests that the mode of action of ICA-1 may not involve ATP- competitive
binding. Thus, our data suggests that ICA-1 is an interesting agent to be tested
on neuroblastoma cell which proliferate via PKC-ι mediated pathway.
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CHAPTER 5
ICA-1 INHIBITS PROLIFERATION AND INDUCES APOPTOSIS OF
NEUROBLASTOMA CELLS
5.1 Introduction
Neuroblastoma is the most common extra cranial tumor diagnosed in
children and in infants [113]. They are multidrug resistant tumors and show poor
prognosis [114]. The primary target of the disease is infants and small children.
The prognosis in is much better in infants as compared to children over a year
whereas in the latter recovery of the patient is rare [52]. Despite significant
research efforts and advanced therapeutic regiments, neuroblastoma control
continues to be a medical dilemma.
We demonstrate that the neuroblastoma cells proliferate via PKCι/Cdk7/cdk2 pathway. ICA-1 treatment resulted in inhibition of this pathway.
Treatment with ICA-1 induced chromatin condensation as shown by 4′, 6diamidino-2-phenylindole (DAPI) staining of the nucleus. ICA-1 also induced
DNA fragmentation which was analyzed using 3′ terminal
deoxynucleotidyltransferase (TdT)- mediated dUTP nick end-labeling (TUNEL)
assay depicting the pro-apoptotic potential of ICA-1. Furthermore, ICA-1
promoted apoptosis of neuroblastoma cells via induction of Caspase-3 activation
and subsequent cleavage of PARP.
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5.2 Results
5.2.1 ICA-1 inhibited the proliferation of BE(2)-C neuroblastoma cells:
Since, our results (Figure 3.3) demonstrated the role of the PKC-ι/Cdk7/cdk2
pathway in the proliferation of neuroblastoma cell line BE(2)-C, we hypothesized
that treatment with ICA-1 should inhibit the proliferation of these cells. We
analyzed the effect of ICA-1 on normal neuronal cells LA1-5s and the
neuroblastoma BE(2)-C cell line. Cell viability assays showed that ICA-1 had no
significant effect on the proliferation of LA1-5s cells (Figure 5.1 A), but
significantly inhibited the proliferation of the neuroblastoma cell line, BE(2)-C by
58% at 48 hours (P=0.01) with an IC50 of 0.1µM (Figure 5.1 B). Furthermore, we
made a comparative study between the effects of ICA-1 with that of ATM on the
two cell lines. Interestingly, we found that ATM (100µM) inhibited the
proliferation of BE(2)-C (Figure 5.2 A). However, this concentration also inhibited
the proliferation of LA1-5s cells (Figure 5.2 B).
5.2.2 ICA-1 inhibited the in-vitro phosphorylation of Cdk7 by PKC-ι: Since,
ICA-1 specifically inhibited PKC-ι activity and PKC-ι is an in-vitro Cdk7 kinase,
we investigated the effect of ICA-1 on phosphorylation of Cdk7. ICA-1 inhibited
the in-vitro phosphorylation of Cdk7 by recombinant PKC-ι (Figure 5.3).
5.2.3 ICA-1 inhibited the proliferation of BE(2)-C neuroblastoma cells by
abrogating the PKC-ι/Cdk7/cdk2 pathway: In order to prove that the molecular
mechanism of ICA-1 is inhibition of the PKC-ι/Cdk7/cdk2 pathway, we analyzed
the effect of ICA-1 (0.1µM) in cell culture. BE(2)-C cells were treated with ICA-1
(0.1µM) for 48 hours with addition of drug every 24 hours. ICA-1 inhibited the
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phosphorylation of Cdk7 by 55% (P=0.001) which further down regulated the
phosphorylation of cdk2 by 65% (P=0.01) (Figure 5.4). Therefore, our data
reveal the possible mechanism by which ICA-1 exhibits its anti-proliferative effect
on BE(2)-C cells.
5.2.4 ICA-1 induces apoptosis in BE(2)-C cells: Since, ICA-1 inhibited the
proliferation of neuroblastoma cells; we tested whether the drug could induce
apoptosis in these cells. BE(2)-C cells treated with ICA-1 (0.1µM) exhibited
chromatin condensation and nuclear fragmentation compared to control cells as
displayed by nuclear staining with DAPI (Figure 5.5 A, B). DNA damage following
ICA-1 treatment was also detected as shown by TUNEL assay. The increase in
fluorescence in response to ICA-1 treatment represents the increase of free 3 ′
OH groups of cleaved DNA (Figure 5.5 C, D). Because ICA-1 induced apoptosis
in neuroblastoma, we further determined whether ICA-1 also induces other
apoptotic responses such as Caspase and PARP cleavage. Treatment of BE(2)C with ICA-1 (0.1µM) induced cleavage of Caspase-3 as shown by Western blot
analysis (Figure 5.5 E). PARP, a downstream target for Caspase-3 was also
cleaved in response to ICA-1 treatment (Figure5.5 E). Thus, our data strongly
suggests that ICA-1 induces apoptosis in BE(2)-C neuroblastoma cells.
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Figure 5.1 A, B ICA-1 inhibits the cell proliferation of BE(2)-C neuroblastoma
cells. LA1-5s and BE(2)-C cells (5x104) were treated with ICA-1 (A, B) from 2472 hours. At the indicated time points, viable cells were counted using Trypan
blue exclusion assay. The control cells were incubated with equal volume of
vehicle control (sterile water). Data represents N=3 independent experiments
and the mean number of viable cells and standard error were plotted.
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Figure 5.2 A, B ATM inhibits the cell proliferation of both normal neuronal and
neuroblastoma cells. LA1-5s and BE(2)-C cells (5x104) were treated with ATM
(A, B) from 24-72 hours. At the indicated time points, viable cells were counted
using Trypan blue exclusion assay. The control cells were incubated with equal
volume of vehicle control (DPBS). Data represents N=3 independent
experiments and the mean number of viable cells and standard error were
plotted.
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Figure 5.3 A, B ICA-1 inhibited the in-vitro phosphorylation of Cdk7 by PKC-ι. (A)
Recombinant active PKC-ι (0.5µg) and active Cdk7 (0.5µg) were subjected to an
in vitro kinase activity assay in the presence of ICA-1 (0.1µM and 5µM). The
expression of pCdk7 (T170) and pan-Cdk7 were determined by Western blot
analysis. (B) Represents the densitometry for the effect of ICA-1 on the in-vitro
phosphorylation of Cdk7 by PKC-ι. Data represents N=3 independent
experiments.

44

Figure 5.4 A, B ICA-1 abrogated the PKC-ι/Cdk7/cdk2 pathway. (A) BE(2)-C
cells treated with ICA-1 (0.1µM) for 48 hour were harvested and whole cell
extracts were prepared. Equal protein (100μg) was loaded on SDS-PAGE
followed by immunoblotting for pCdk7 (T170) and pcdk2 (T160) pan-Cdk7, pancdk2, PKC-ι and β-actin to examine the difference between control cells (-) and
ICA-1 treated cells (+). (B) Represent the densitometry for the decrease in the
pCdk7 and pcdk2 upon ICA-1 treatment. Data represents N=3 independent
experiments.
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Figure 5.5 A, B, C, D ICA-1 induces apoptosis in BE(2)-C cells. (A, C) depict
cells treated with vehicle control. (B, D) depict cells treated with ICA-1 (0.1µM).
(A, B) Cells were stained with DAPI to visualize the cellular nuclei. (C, D) Cells
were subjected to TUNEL assay. Data represents N=3 independent
experiments.
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Figure 5.5 E ICA- 1 induces apoptosis in BE(2)-C cells. (E) BE(2)-C cells were
treated with either vehicle control or ICA-1 (0.1µM) for 24, 48 and 72 hours. At
the indicated time points, whole cell extracts were prepared followed by SDSPAGE and subsequently Western blotting for Caspase-3 activity and PARP
cleavage. β-actin levels were used as loading control. Data represents N=3
independent experiments.
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5.3. Summary
ICA-1 specifically inhibited the proliferation of neuroblastoma cells and did
not have a significant effect on the proliferation of normal neuronal cells.
However, ATM inhibited the proliferation of both cells. Thus, our data supports
that ICA-1 is less toxic than ATM. ICA-1 inhibited the capacity of PKC-ι as an invitro Cdk7 kinase as well as inhibited the PKC-ι/Cdk7/cdk2 pathway in BE(2)-C
cells. The inhibition of proliferation was accompanied by induction of apoptosis.
Thus, ICA-1 inhibits the proliferation and induces apoptosis in
neuroblastoma cells.
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CHAPTER 6
SELF REGULATION OF PKC-ι
6.1 Introduction
PKC family of serine/threonine kinases are involved in many cellular
responses such as proliferation, differentiation, motility, and survival. Different
PKC iosoforms have been reported to be involved in different types of cancers
like brain, neuroblastoma, prostate, etc. [115]. However, the knowledge
regarding the transcriptional and translational regulation of PKCs is still
rudimentary. The promoters of several PKCs (α, β, γ) have been cloned till date,
but few have been linked to cancer [116-120]. Among the PKC family, PKC-ι is
the only isoform that has been proven to be an oncogene [58, 59]. It is the most
common genomic amplicon as identified by comparative genomic hybridization
[60]. The expression of PKC-ι has been reported to be elevated in many cancers
such as lung [61], breast [66], ovarian [67-69], prostate [70], brain [71], etc. The
expression of PKC-ι is regulated by Bcr-Abl [121].
6.1.1 Bcr-Abl: The translocation of the abl tyrosine kinase gene from the
long arm of chromosome 9 to the breakpoint cluster region (bcr) of chromosome
22, the Philadelphia chromosome is the genetic cause of Chronic myelogenous
leukemia (CML) [122]. Ninety five percent of CML patients test positive for the
mutation in Philadelphia chromosome [123]. Numerous forms of bcr-abl result
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from various breakpoints in the bcr genes [123]. The 210-kDa p210bcr-abl gene
is the most common form while 185-kDa p185bcr-abl is diagnosed in 25% of
CML patients [123]. Bcr-Abl regulates a plethora of signaling pathways,
however, resistance to apoptosis associated with Bcr-Abl-is dependent on the
Ras/MEK and PI 3-kinase pathways [124, 125] (Figure.6.1) Among the PKC
family, PKCβII is essential for Bcr-Abl mediated CML cell proliferation whereas
PKCι promotes Bcr-Abl-mediated resistance to drug-induced apoptosis [121,
126, 127].

Figure 6.1 Bcr-Abl activates both PI3K and MAPK pathways. Adapted from
[124]
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Activation of the ELK-1 consensus sequence near the promoter region of
PKC-ι is it the target of Bcr-Abl in the regulation of PKC-ι expression [121].
Regulation of PKC-ι by Bcr-Abl has been shown to regulate the activation of the
transcription factor ELK-1 which is downstream of Ras/MEK pathway [121].
(Figure 6.2)

Figure 6.2 Bcr-Abl mediated regulation of PKC-ι expression. Adapted from [128]
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6.1.2 Ets family: Ets family of transcription factors play vital role in
coordinating cellular responses and gene expression [129]. A characteristic
feature of the Ets family is a conserved winged helix-turn-helix DNA binding
domain [130-132]. They are the downstream target of MAPK pathways [131].
The Ets family can be divided into two major groups [129].
The first group is comprised of Ets1, Ets2 and Pointed. These have a
conserved C-terminal DNA binding domain and a N-terminal domain referred to
as pointed domain which houses the single MAP phosphorylation site [133, 134]
The second group is the ternary complex factors (TCFs): These include
Elk1, Sap1a, Sap1b, Fli1and Net. They have a transactivation domain that can
be phosphorylated by MAPK at multiple serine and threonine residues. [135,
136].
The Ets family mediate their transcriptional activity by binding to specific
sequences called the Ras-response element (RRE) or serum-response elements
(SRE) that are located near the promoter region of various genes [129].
6.1.3 Elk-1: Among the Ets family members, Elk-1 is a crucial molecule
because it is activated by all three MAPK pathways, namely, p38, JNK and ERK
[137-139]. JNK and ERK phosphorylate different residues in the C-domain of
Elk-1 while the docking site for p38 is still unknown [140, 141].
Alternate to the Bcr-Abl mediated regulation of PKC-ι expression, we
hypothesize that PKC-ι may self regulate its expression by directly associating
with ERK and promoting its translocation to the nucleus where it activates the
transcription factor Elk-1.
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6.2 Results
6.2.1 Expression of PKC-ι and Elk-1 is higher in actively proliferating
neuroblastoma cells: To analyze whether there is a correlation between the
expression profile of PKC-ι and Elk-1 in neuroblastoma, we primarily determined
the expression of PKC-ι and Elk-1 in neuroblastoma cells. The expression of
PKC-ι was higher in actively proliferating malignant neuroblastoma BE(2)-C and
LA-55n cells as compared to serum starved cells. However, the expression of
PKC-ι in non-malignant neuroblastoma LA-15s cells was reverse, that is, PKC-ι
expression in actively proliferating cells was less than serum staved cells. Next,
we analyzed the expression of the transcription factor Elk-1 in these cells. The
expression of Elk-1 corresponded with the expression profile of PKC-ι. In case of
malignant neuroblastoma cells, Elk-1 expression was higher in actively
proliferating cells while in non-malignant cells, the expression was higher in
serum starved cells (Figure.6.3).
The data suggests that there is correlation between expression of PKC-ι
and Elk-1 in neuroblastoma.
6.2.2 PKC-ι directly associated with Elk-1 in actively proliferating cells:
Since, there was a correlation between expression of PKC-ι and Elk-1 in
neuroblastoma, we further analyzed if there was an association between the two
proteins. Immnunoprecipitation studies showed that the association between
PKC-ι and Elk-1 coincided with the expression pattern of the two proteins in
neuroblastoma cells. The association was higher in actively proliferating
malignant neuroblastoma BE(2)-C and LA-55n cells as compared to serum
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starved cells. However, the expression of PKC-ι in non-malignant neuroblastoma
LA-15s cells was reversed, the association was more robust in serum staved
cells than actively proliferating cells (Figure.6.4).
Thus, our data suggests a crosstalk between PKC-ι and Elk-1.
6.2.3 Subcellular association of PKC-ι and Elk-1: Since, the association
between PKC-ι and Elk-1 was higher in actively proliferating malignant
neuroblastoma cells; we analyzed the subcellular association between the two
proteins. Our hypothesis was that PKC-ι would associate with cytoplasmic Elk-1
and promote its nuclear translocation. The association of PKC-ι and Elk-1 was
higher in the nuclear fraction of actively proliferating BE(2)-C neuroblastoma cells
suggesting that PKC-ι may not influence the nuclear translocation of Elk-1
(Figure 6.5).
6.2.4 Sub-cellular expression of PKC-ι and Elk-1: Since the nuclear
association between PKC-ι and Elk-1 was more robust than their cytoplasmic
association, our new hypothesis was that PKC-ι could translocate into the
nucleus and directly activate the transcription factor Elk-1. Thus, the rationale
was that the nuclear expression of the two proteins should be higher in activlely
proliferating cells. Analysis of the subcellular fractions of actively proliferating
LA1-55n and BE(2)-C malignant neuroblastoma cells demonstrated that the
expression of PKC-ι was higher in the nucleus as compared to the cytoplasm. In
the case of serum starved cell, the expression of PKC-ι was higher in the
cytoplasm (Figure 6.6 A, B). This data suggested that in actively proliferating
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neuroblastoma cells, PKC-ι translocates to the nucleus and directly activates the
transcriptional activity of Elk-1.
6.2.5 PKC-ι indirectly phosphorylates Elk-1: In order to test our hypothesis
that PKC-ι can directly activate Elk-1, we analyzed the capacity of PKC-ι as an
Elk-1 kinase. Recombinant active PKC-ι did not directly phosphorylate
recombinant active Elk-1. However, the phosphorylation of Elk-1 by ERK1 was
increased in the presence of recombinant active PKC-ι (Figure 6.7). This
suggested that PKC-ι could indirectly promote the phosphorylation of Elk-1 in
ERK-1 dependent manner.
6.2.6 Association of PKC-ι and ERK1 in neuroblastoma cells: Since, PKC-ι
promoted the in-vitro phosphorylation of Elk-1 in ERK-1 dependent manner we
analyzed the association between PKC-ι and ERK1 in neuroblastoma cells.
Immnunoprecipitation studies showed that the association between PKC-ι and
ERK1 coincided with the association of PKC-ι and Elk-1. The association was
higher in actively proliferating malignant neuroblastoma LA1-55n cells as
compared to serum starved cells (Figure.6.8). This data suggested that PKC-ι
could regulate is expression by regulating the activity of ERK-1.
6.2.7 Subcellular expression ERK1 in neuroblastoma cells: Our data
suggested that PKC-ι could regulate the activity of ERK1 and its downstream
target Elk-1. Thus, the rationale was that there should be a correlation between
the subcellular expression of the PKC-ι and ERK1. Analysis of the subcellular
fractions of actively proliferating malignant neuroblastoma LA1-55n cells
demonstrated that the expression of ERK1 was higher in the nucleus as
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compared to the cytoplasm. In the case of serum starved cell, the expression of
ERK1 was higher in the cytoplasm (Figure 6.9).

Figure 6.3 Expression of PKC-ι and Elk-1 is higher in actively proliferating
neuroblastoma cells. Endogenous levels of PKC-ι in malignant neuroblastoma
cells, BE(2)-C and LA1-55n and non-malignant cells, LA1-5s were determined by
Western blot analysis Equal amounts of cellular proteins (100µg) from actively
proliferating (50%) and contact inhibited (100% S) cells were loaded in each well
and immunoblotted for PKC-ι and Elk-1. β-actin levels were analyzed as a
loading control. Data is representative of N=2 independent experiments.
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Figure 6.4 Association of PKC-ι and Elk-1 in neuroblastoma cells. PKC-ι (5µg)
was immunoprecipitated from LA1-5s non-malignant neuroblastoma cells as well
as BE(2)-C and LA1-55n malignant neuroblastoma cells. The samples were
subjected to in-vitro kinase activity assay and were analyzed for pElk-1 and pan
Elk-1 using Western blot analysis. Data is representative of N=2 independent
experiments.

Figure 6.5 Association of PKC-ι and Elk-1 in subcellular fractions of
neuroblastoma cells. PKC-ι (5µg) was immunoprecipitated from BE(2)-C
malignant neuroblastoma cells. They samples were analyzed for pan Elk-1 using
Western blot analysis. Data is representative of N=2 independent experiments.
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Figure 6.6 A, B Subcellular expression of PKC-ι and Elk-1 in neuroblastoma
cells. Endogenous levels of PKC-ι and Elk-1 in malignant neuroblastoma cells,
LA1-55n and BE(2)-C cells were determined by Western blot analysis Equal
amounts of cellular proteins (30µg) from subcellular fractions of actively
proliferating (50%) and contact inhibited (100% S) cells were loaded in each well
and immunoblotted for PKC-ι and Elk-1. Histone H1 was used as a purity control
for the experiment. Data is representative of N=2 independent experiments.
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Figure 6.7 PKC-ι indirectly phosphorylates Elk-1. Recombinant active PKC-ι
(0.5μg) and active Elk-1 (0.5μg) in the presence (column 3) and absence
(column 1) of recombinant active ERK1 were subjected to an in-vitro kinase
activity assay. ERK1 and Elk-1 (second column) was the positive control. The
proteins were then separated by SDS-PAGE and Western blotted to determine
the phosphorylation of Elk-1 at T170. Data represents N=2 independent
experiments.

Figure 6.8 Association of PKC-ι and ERK1 in neuroblastoma cells. PKC-ι (5µg)
was immunoprecipitated from LA1-5s non-malignant neuroblastoma cells as well
as BE(2)-C and LA1-5s malignant neuroblastoma cells. The samples were
subjected to in-vitro kinase activity assay and were analyzed for pERK1 and pan
ERK1 using Western blot analysis. Data is representative of N=2 independent
experiments.
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Figure 6.9 Subcellular expression ERK1 in neuroblastoma cells. Endogenous
levels of ERK1 in malignant neuroblastoma LA1-55n cells were determined by
Western blot analysis Equal amounts of cellular proteins (30µg) from subcellular
fractions of actively proliferating (50%) and contact inhibited (100% S) cells were
loaded in each well and immunoblotted for ERK1 and β-actin.
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6.3 Summary
Based on our data, we hypothesize that in contrast to Bcr-Abl mediated
regulation of PKC-ι, PKC-ι can directly regulate the transcriptional activity of Elk1, thereby self-regulating its expression.
Our hyphothesis can be summarized by the following diagram:

Figure 6.10 Self-regulation of PKC-ι. We hypothesize that PKC-ι translocates into
the nucleus in actively proliferating neuroblastoma cells where it activates ERK1.
This promotes the activation of its downstream target Elk-1 which subsequently
upregulates the expression of PKC-ι.

61

CHAPTER 7
DISCUSSION AND FUTURE DIRECTIONS
7.1 Discussion
Very little research has been conducted using PKC-ι specific inhibitors.
To date, the only compounds identified as inhibitors of atypical PKC isoforms are
aurothiomalate (ATM) and aurothioglucose. ATM, which is currently in phase I
clinical trial evaluation for lung cancer (sponsored by NCI) has IC50 ranging from
~0.3 µM – >100 μM [111]. However, ATM has not been shown to act specifically
on PKC-ι versus ζ, and the mechanism of action for ATM is not fully understood,
as shown by its off target effects. PKC-ι and PKC-ζ are 84% homologous with
respect to the amino acid sequences of their catalytic domain [56] making it very
difficult to synthesize an inhibitor that is specific. Nevertheless, in this study the
sequence targeted for molecular docking was amino acid residues 469-475
(glutamine, isoleucine, arginine, isoleucine, proline, arginine and serine). The
molecular docking method was based on an experimental design that included
rapid functional testing of specificity between PKC isoforms as the primary step
of in vitro screening. This important aspect of the approach eliminates
candidates that bind the ATP binding pocket (which is conserved between PKC
isoforms). Although it is straightforward to model numerous potential interactions
by molecular docking in silico, such as docking molecules into the ATP binding
site or other surfaces, our approach pinpointed the most diverse structural
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elements in PKC-ι and purposefully evaluated specificity in vitro to avoid
compounds that interact with structural features that are common to PKC
isoforms such as the ATP binding pocket. This directed molecular docking
approach has been successfully used in a number of studies [142]. The current
study established the chemotherapeutic potential of the novel PKC-ι inhibitor,
ICA-1. Comparative study of ICA-1 and ATM showed that ICA-1 specifically
inhibited the activity of only PKC-ι, whereas ATM exhibited inhibitory effects on
both PKC-ι and PKC-ζ, suggesting non-specificity of the drug. The IC50 of ATM
was 100µM which is 1000 times more than the IC50 for ICA-1. Furthermore, the
PIP3 activation assay showed that ICA-1 specifically inhibited the activity of PKC-ι
with an IC50 of 0.01 µM. Since this assay measures the femtomoles of (γ-32P)
ATP transferred, it was possible to measure the efficacy of ICA-1 over a broad
range of concentrations yielding the most sensitive data. However, we did not
test the inhibitory effect of ATM using PIP3 activity assay because lower
concentrations of ATM did not exhibit any effects on the activity of either PKC-ι or
PKC-ζ. The structure of ICA-1 is similar to FDA approved chemotherapeutic
drug Fludarabine, administered as 5′-nucleotide monophosphate [143]. Thus, we
speculate that ICA-1 may be transported into the cell by a mechanism that
utilizes a nucleoside transporter similar to Fludarabine [144].
Previously, we found that PKC-ι is overexpressed in actively proliferating
prostate cancer and glioma cells [71, 73]. Similarly, we found higher expression
of PKC-ι in adrenal neuroblastoma tissue as well as neuroblastoma cells
suggesting the involvement of PKC-ι in the proliferation of neuroblastoma cells.
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Phenotypically, neuroblastoma cells can be divided into 3 distinct groups:
sympathoadrenal neuroblasts (N-type that form slow growing tumors), nonneuronal precursor cells (S-type which are non-malignant) and I-type which are
morphologically intermediate to that of N and S cells. I-type cells possess the
biochemical properties of both N and S cells [145]. Thus, the rationale behind
our choice of BE(2)-C cells (I-type) was to ensure that our results are
representative of all the major neuroblastoma phenotypes. The S-type have
been shown to be normal neuronal cells [146]. Thus, LA1-5s cells were used as
control to analyze the toxicity of ICA-1.
To determine the mechanism underlying the anti-proliferative action of
ICA-1, we first identified a signaling pathway by which PKC-ι may promote
constitutive proliferation of BE(2)-C cells. We focused on investigating the role of
cdks since they are involved in regulation of cell cycle progression [78]. Our data
suggest that PKC-ι is an in-vitro Cdk7 kinase. Endogenously, PKC-ι directly
associated and phosphorylated both Cdk7 as well as its downstream target cdk2
suggesting that PKC-ι is regulating or promoting neuroblastoma cell proliferation
via the PKC-ι/Cdk7/cdk2 pathway. Hence, this pathway was targeted to verify
the efficacy of ICA-1.
We were not able to obtain the effects of ICA-1 on the cell cycle because
of the BE(2)-C cells grow in clusters. The results obtained from cell cycle
analysis by flow cytometry yielded a very high percentage of aggregates making
it impossible to determine the significance of the data (n=8) (data not shown).
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Collectively, our data exhibit the potential of ICA-1 as a novel PKC-ι
inhibitor. The efficacy of ICA-1 at such low concentration (0.1µM) and its
negligible effect on normal neuronal cells suggests its potential as a
chemotherapeutic with little toxicity. Therefore, future studies will investigate the
effects of ICA-1 on an in-vivo mouse model to establish the feasibility of
advancing ICA-1 to clinical trials. Furthermore, PKC-ι expression should be
useful as a biomarker for neuroblastoma when treating patients with anti-PKC-ι
therapy (with ICA-1 or one of its derivatives) for personalized medicine.
Bcr-Abl has been shown to regulate the activation of the transcription
factor ELK-1 which in turn regulates the expression of PKC-ι [121]. Alternatively,
we hypothesize that PKC-ι self regulates its expression by indirectly regulating
the activity of ELK-1. Our preliminary data shows that the expression of PKC-ι
and Elk-1 were higher in actively proliferating LA1-5S (non-malignant), BE(2)-C
and LA1-55n (malignant )neuroblastoma cells. Immunoprecipitation studies
show that association of PKC-ι with phosphorylated Elk-1 was more robust in
these cells suggesting a crosstalk between the two proteins. Analysis of the
subcellular association of these two proteins revealed increased association
between PKC-ι and Elk-1 in the nucleur fraction of actively proliferating BE(2)-C
cells as compared to cytoplasm. Interestingly, the nuclear expression of PKC-ι
was also found to be higher in these cells, sugeesting that PKC-ι translocated to
the nucleus in actively proliferating cells and regulated the transcriptional activity
of Elk-1. Although, recombinant active PKC-ι did not phosphorylate recombinant
active Elk-1, it increased the phosphorylation of Elk-1 in the presence of ERK1,
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an upstream kinase of Elk-1 in the Bcr-Abl mediated PKC-ι regulatory pathway.
Thus, our data suggested that ERK1 was integral to the self-regulatory activity of
PKC-ι. Furthermore, expression of ERK1 was also found to be higher in the
nuclear fraction of our actively proliferating model cell systems.
In conclusion, we propose a novel self-regulatory mechanism of PKC-ι in
neuroblastoma cells. We hypothesize that the self-regulation of PKC-ι
commences with the translocation of PKC-ι into the nucleus where it promotes
the activation of ERK1. This culminates in increased activation of Elk-1, a
downstream target of ERK1 and subsequent upregulation in the expression of
PKC-ι. Our hypothesis can be summarized as PKC-ι/ ERK1/ Elk-1/ PKC-ι
pathway (Figure 6.10)
7.2 Suggestions for future studies
•

Determine the potency of ICA-1 in-vivo

•

Study the effect of ICA-1 on other cancers models such as
prostate, breast cancer, ovarian cancer, etc.

•

Analyze the pharmacodynamics and pharmacokinetics of ICA-1

•

Examine the effect of ICA-1 on other Protein kinase C isozymes

•

Evaluate the effect of ICA-1 on other protein kinases

•

Investigate the effect of other protein kinase C in neuroblastoma

•

Analyze the role of PKC-ι in neuroblastoma cell survival

•

Investigate the effect of ICA-1 on the self regulation of PKC-ι

•

Study the effect of PKC-ι on the regulation of other members of the Ets
family.
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CHAPTER 8
MATERIALS AND METHODS
8.1 Reagents
ICA-1 or [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3dihydroxycyclopentyl]methyl dihydrogen phosphate was synthesized and
purchased from Southern Research Institute (Birmingham, AL). It was dissolved
in sterile distilled water (vehicle) before use. Recombinant PKC-ι and
recombinant PKC-ζ active enzymes were purchased from Millipore (Temecula,
CA). Myelin basic protein (MBP) was purchased from Sigma (St. Louis, MO).
PKC-ι antibody was purchased from BD Biosciences (San Jose, CA). The
antibodies to phospho-MBP (pMBP) (Thr 98), MBP, PKC-ζ, pElk-1 were
purchased from Millipore. PKC activity assay kit was purchased from Assay
Designs (Ann Arbor, MI). For the 32P labeling, recombinant PKC-ι from BioVision
(Mountain View, CA), PIP3 [Phosphatidylinositol (3,4,5)-trisphosphate] from
Avanti Polar Lipids (Alabaster, Al), (γ-32P)ATP from NEN Life Science Products
Inc. (Boston, MA) and PKC-ε Pseudosubstrate from (Invitrogen Inc.) were used.
The antibodies to Cdk7, phospho-cdk2 (pcdk2, Thr 160), Caspase-3, Elk-1, ERK1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). pCdk7 (Thr
170) antibody was purchased from Abcam (Cambridge, MA). The antibodies
purchased from Cell Signaling were: PARP and cleaved PARP. Enhanced
chemiluminescence (Supersignal West Pico Chemiluminescent Substrate) was
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purchased from Pierce (Rockford, IL). Dulbecco’s phosphate buffered saline
without Mg2+ and Ca2+ (DPBS) and Trypsin-EDTA (ethylenediaminetetraacetic
acid) solution was purchased from Fisher Scientific (Norcross, GA).
8.2 Cell culture
Phenotypically, neuroblastoma cells can be divided into 3 distinct groups:
sympathoadrenal neuroblasts (N-type that form slow growing tumors), nonneuronal precursor cells (S-type which are non-malignant) and I-type which are
morphologically intermediate to that of N and S cells. I-type cells possess the
biochemical properties of both N and S cells [145]. The S-type have been shown
to be normal neuronal cells [146]. Thus, LA1-5s cells were used as control to
analyze the toxicity of ICA-1.
BE(2)-C human neuroblastoma cells, were obtained from the American
Tissue Culture Collection (Rockville, MD). These cells are clones of the SK-NBE(2) human neuroblastoma cell line [147]. Phenotypically, they are classified
as I-type neuroblastoma cells [145]. [145]. LA1-5s and LA1-55n cells were
obtained from Dr. Robert Ross’ laboratory in Fordham University, NY. Cells (2x
106) were grown as a monolayer in 75 cm2 tissue culture flasks and maintained
at 37˚C in a humidified atmosphere comprised of 5% CO2.The complete growth
medium was 89% by volume of 1:1 mixture of Eagle's Minimum Essential
Medium from ATCC and Ham's F12 Medium from Invitrogen corporation
(Carlsbad, CA). Additionally, the media was supplemented with 10% fetal bovine
serum from ATCC and 1% antibiotics (Penicillin 10 U/ml and streptomycin
10µg/ml from Fisher Scientific, Norcross, GA.
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8.3 Atypical PKC profiling
Preliminary work was performed on neuroblastoma tissues obtained from
the Nationwide Children's Hospital Biopathology Center. The expression of PKCι in adrenal neuroblastoma (n=11) was compared to normal adrenal biopsies
(n=11). Furthermore, actively proliferating BE(2)-C cells (50% confluent) were
harvested and cell lysates were prepared as described in the
‘Immunoprecipitation and Western Blot analysis’ section. Another set of cells
were grown until contact inhibition was achieved (100% confluent).
Subsequently, the cells were washed twice with DPBS, followed by addition of
starved media (absence of fetal bovine serum) for an additional 48 hours. Cells
were then harvested and cell lysates were prepared. Proteins (100µg) from both
sets of cell lysates were separated by SDS-PAGE and immunoblotted for PKC-ι
and PKC-ζ with specific antibodies.
8.4 Cell fractionation and Western Blot Analysis
Cells were placed on ice to terminate the incubation. The cells were
washed twice with DPBS and then scraped at 4˚C, resuspended and sonicated in
300μl of homogenization buffer (50 mM HEPES at pH 7.5), 150 mM NaCl, 1 mM
EDTA and 2 mM EGTA [glycol-bis(2-aminoethylether)-N, N, N’, N’-tetraacetic
acid], 0.5% Triton-X 100, 1 mM sodium orthovanadate, 0.5 M NaF, 0.2 M PMSF
(phenylmethylsulphonylfluoride), 1mM DTT (dithiothreitol) and 0.15 U/ml
aprotinin [148]. The cell suspension was centrifuged at 16,000 g for 30 minutes
to obtain cell extracts. The protein content was measured according to Bradford
[149]. Protein samples were separated by 12% on sodium dodecyl sulfate69

polyacrylamide gel electrophoresis (SDS-PAGE) (1.5mm thick gel) using Protean
II xi 16cm gel loading system (BioRad) and electrophoresed at 160volts and
subsequently transblotted by electroblotting with transfer buffer 100 ml of 10 x tris
glycine (0.25 M tris and 1.92 M glycine) and 20% methanol in 1 L of distilled
water and electroblotted for one hour at 24 volts. For Western blot analysis,
each blot was blocked for 1 hour with 5% (w/v) fat-free dry milk in tris-buffered
saline with 0.05% tween-20 (TBST) solutions at room temperature. Protein
bands were probed with primary antibody in 5% milk in blocking buffer at 4°C
overnight. The primary antibodies dilutions were 1:1000-1:5000. Membranes
were subsequently washed three times for 15 minutes with TBST. Secondary
antibodies such as horseradish-peroxidase-conjugate anti-mouse, anti-rabbit or
anti-goat were diluted 1:1000 in 5% milk TBST. The membranes were incubated
with secondary antibody (1:5000) at room temperature for 1 hour.
Immunoreactive bands were visualized with SuperSignal West Pico
Chemiluminescent substrate.
8.5 Densitometry
The intensity of each band was measured using the Quantity one, 1-D
analysis software (BioRad Laboratories). In order to derive the correct intensity
of each band, the background intensity was subtracted from the band intensity.
Mean absorbance of three independent studies were compared by means of
Student’s t-test to determine the statistical significance of the data.
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8.6 Inhibition of PKC-ι with siRNA
The siRNA was a pool of 3 target-specific 19-25 nucleotides siRNAs
designed to knock down PKC-iota gene expression. Each vial contains 3.3 nmol
of lyophilized siRNA, sufficient for a 10 μM solution once resuspended using
company protocol. Their mRNA sequences were:
663:5-CAAGCCAAGCGUUUCAACA-3’
5’-UGUUGAAACGCUUGGCUUG- 3’
729: 5’-GGAACGAUUGGGUUGUCAU-3’
5’-AUGACAACCCAAUCGUUCC-3’
2137:5’-CCCAAUAUCUUCUCUUGUA-3’
5’-UACAAGAGAAGAUAUUGGG-3’
These were designed by Santa Cruz Biotechnology. BE(2)-C cells (5 x
104) were plated and grown in 25 cm2 tissue culture plates. Twenty four hour
post-plating cells were transfected with either control siRNA sequences
(containing scrambled sequence which does not lead to specific degradation of
any known cellular mRNA; sequence not revealed by Santa Cruz Biotechnology)
or PKC-ι gene silencing sequences (150nM). Cell viability was determined over
a time period of 24, 48 and 72 hour. Cell viability was performed as using Trypan
Blue Exclusion assay. To analyze the effect of siRNA on PKC-ι expression, cells
(2x105) were treated with PKC-ι siRNA for 48 hours and then total lysate were
prepared. The protein (100µg) was separated by SDS-PAGE followed by
Western blot to determine the expression of PKC-ι and PKC-ζ. To determine the
effect of PKC-ι siRNA on the phosphorylation of Cdk7, the protein was
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immunoprecipitated using Cdk7 antibody (5µg) and subjected to Western blot
analysis.
8.7 In-vitro kinase activity assay to analyze the phosphorylation of Cdk7 by
PKC-ι
The recombinant active PKC-ι (0.5μg) and Cdk7 (0.5µg) purchased from
Millipore (Temecula, CA) were suspended in 200μl of PKC kinase buffer [150] to
test the ability of PKC-ι as an in-vitro Cdk7 kinase. The reaction was terminated
after incubation for 10 min at 30°C by placing the samples in ice and adding
sample loading buffer. Samples were then fractionated by SDS-PAGE and
immunoblotted via Western Blot analysis.
8.8 Immunoprecipitation
Cells were placed on ice to terminate the incubation. The cells were
washed twice with DPBS and then scraped at 4˚C, resuspended and sonicated in
300μl of homogenization buffer (50 mM HEPES at pH 7.5), 150 mM NaCl, 1 mM
EDTA and 2 mM EGTA [glycol-bis(2-aminoethylether)-N, N, N’, N’-tetraacetic
acid], 0.5% Triton-X 100, 1 mM sodium orthovanadate, 0.5 M NaF, 0.2 M PMSF
(phenylmethylsulphonyl-fluoride), 1mM DTT (dithiothreitol) and 0.15 U/ml
aprotinin [148]. The cell suspension was centrifuged at 16,000 g for 30 minutes
to obtain cell extracts. The protein content was measured according to Bradford
[149]. Approximately 200μg of protein was immunoprecipitated with affinity
purified antibodies (5μg). Cell lysates were first subjected to pre-clearance by
incubation with agarose beads for 30 minutes at 4°C. The cell lysates were
subsequently incubated with 5μg of either PKC-ι or Cdk7 antibody or both in case
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of co-immunoprecipitation. The immune complexes were rocked overnight at
4°C and further incubated at 4°C for 2 hours with IgG-agarose beads specific to
the strain of primary antibody. Post incubation, the beads were washed three
times with 1mL of complete lysis buffer. Samples were then separated on 12%
SDS-PAGE and transblotted onto a nitrocellulose membrane. The proteins were
detected by Western blot analysis.
8.9 Database preparation
The National Cancer Institute/Developmental Therapeutics Program
(NCI/DTP) maintains a repository of 139,644 samples (the plated compound set).
The three-dimensional coordinates for the NCI/DTP plated compound set in the
MDL sd format was converted to the mol2 format by the program SDF2MOL2
(UCSF). Partial atomic charges for the ligands were calculated using SYBDB
(UCSF) and added to the plated compound set mol2 file. This was performed by
David Ostrov, Ph. D. at the University of Florida.
8.10 Molecular docking
Molecular docking was done by selecting specific structural pockets in
PKC-ι protein that may be suitable for interactions with drug-like small molecules.
Molecular docking simulations where each one of approximately 300,000 small
molecules (MW < 500) is positioned in the selected structural pocket and scored
based on predicted polar (e.g., H bond) and non-polar (e.g. Van der Waal’s)
interactions. The 30 top scoring compounds for each selected structural pocket
were obtained for use in functional assays. The grid based scoring method sums
the attractive and repulsive forces between atoms in each docked small molecule
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and the site selected for molecular docking. Interactions between charges on
atoms in ICA-1 with amino acids are computed as an electrostatic score. The
electrostatic score and van der Waals scores are summed to generate an overall
energy score which was used to rank the highest scoring compounds.
Docking calculations were performed with the October 15, 2002 version of
DOCKv5.1.0. The coordinates for the crystal structure PKC, PDB code 1ZRZ,
were used. The molecular surface of the structure was explored using sets of
spheres to describe potential binding pockets. The spheres literally fill in the
available pocket spaces where a ligand might be able to form a complex. DOCK
uses the spheres as guides to search for orientations of each molecule that fit
into the selected sites. The sites selected for molecular docking were defined
using the SPHGEN/SITESELECTOR programs and filtered through the
CLUSTER program. The SPHGEN program generates an unbiased grid of
points that reflect the actual shape of the selected site. The CLUSTER program
groups the selected spheres to define the points that are used by DOCK to
match (superimpose) potential ligand atoms with spheres. Twenty two spheres
were used to define the PKC-ι site for molecular docking. Each compound in the
NCI/DTP repository was positioned in the selected site in 1000 different
orientations. Intermolecular AMBER energy scoring (vdw + columbic), contact
scoring and bump filtering implemented in DOCKv5.1.0. PYMOL were used to
generate molecular graphic images. All molecular docking jobs were performed
on a high performance supercomputer at the University of Florida running linux.
This was performed by David Ostrov, Ph. D. at the University of Florida.
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8.11 Phosphorylation of MBP by recombinant active PKC-ι or recombinant
active PKC-ζ enzymes
The PKC-ι or PKC-ζ (0.01μg/μl) was incubated with different
concentrations of ICA-1 (0.1 µM, 1 µM or 5 µM) for 10 min at 4°C. This was
followed by incubation at 30°C in 200μl of PKC kinase buffer [150] to test the
ability of these PKC isoforms to phosphorylate a final concentration of 0.025
mg/ml MBP, a known substrate for PKCs [112]. The reaction was terminated
after 10 min by placing the samples in ice and adding sample loading buffer.
Samples were then fractionated by SDS-PAGE and immunoblotted.
8.12 PKC activity assay kit
The selectivity of ICA-1 and ATM for PKC-ι versus PKC-ζ were compared
using a PKC activity assay kit (Assay Designs). The recombinant active PKC-ι
(0.01µg) or PKC-ζ (0.01µg) were incubated with different concentrations of ICA-1
(0.1 µM, 1 µM or 5 µM) or ATM (0.01µM, 0.1µM, 1µM or 100µM) for 10 min at
4°C followed by incubation with phosphatidylserine (5μg) and ATP (0.0025
mg/ml) for 30 min at 30°C. The remaining steps were per the manufacturer’s
protocol.
8.13 32P labeling
Briefly, 0.01µg of recombinant active PKC-ι was treated with different
concentrations of ICA-1 for 10 min at 4°C before adding 10 fM PIP3 ,
phosphatidylserine (4µg), (γ-32P)ATP (50 µmol/L) and as substrate, serine analog
of the PKC-ε pseudosubstrate (40 µmol/L). This mixture was suspended in 100µl
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of reaction mixture composed of Tris-HCl (50 mmol/L at pH 7.5), (sodium
orthovandate) Na3VO4 (100µmol/L), (sodium phosphate) Na2P2O7 (100µmol/L),
(sodium fluoride)NaF (1 mmol/L), (phenylmethanesulfonylfluoride) PMSF
(100µmol/L) and (magnesium chloride) MgCl2 (5 mmol/L) followed by incubation
for 10 min at 30°C. After incubation, the 32P labeled substrate was trapped on P81 filter paper and counted in a liquid scintillation counter.
8.14 Competitive inhibitory assay
The assay was performed using an ELISA plate which was coated by
incubating with1µg of phospho-MBP (pMBP) (T98) overnight at 4⁰C. The
antibody dilution buffer used was 3% BSA (Bovine serum albumin). Twenty-four
hours post-incubation, the wells were washed 3-4 times with DPBS buffer and
blocked with 200µl of antibody dilution buffer at room temperature for 2 hour.
Recombinant active PKC-ι (0.01μg/μl) was incubated with or without ICA-1
(1 µM) for 10 min at 4°C prior to addition of 50μl of PKC kinase buffer [150] to
test the inhibitory effects of ICA-1 on PKC-ι activity utilizing varying
concentrations of MBP (0.0025 mg/ml, 0.05 mg/ml, 0.010 mg/ml and 0.02
mg/ml). This reaction was performed in separated tubes and terminated after 10
min incubation at 30°C by placing the samples in ice. The reaction cocktail was
subsequently transferred to the ELISA plate (primary antibody bound) and
incubated at room temperature for 2 hours. The wells were washed 3-4 times
with DPBS buffer and incubated with secondary antibody at room temperature for
1 hour. Subsequently, wells were washed 3-4 times with DPBS buffer and
incubated with tetramethylbenzidine (TMB) reagent for 1 hour at room
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temperature. Acid stop solution was added to each well and the absorption was
measured at 450nm.
8.15 In-vitro kinase activity assay to analyze the effect of ICA-1 on the
phosphorylation of recombinant Cdk7 by recombinant PKC-ι
The recombinant active PKC-ι (0.5μg) and Cdk7 (0.5µg) were purchased
from Millipore (Temecula, CA) and were suspended in 200μl of PKC kinase
buffer [150] to test the ability of these PKC-ι as an in-vitro Cdk7 kinase. The
same reaction was repeated in the presence of ICA-1 drug (0.1uM, 1µM and
5uM). In both the experiments, the reaction was terminated after incubation for
10 min at 30°C by placing the samples in ice and adding sample loading buffer.
Samples were then fractionated
8.16 Cell viability assay
LA1-5s and BE(2)-C cells (5x 104) were cultured in 25 cm2 tissue culture
flasks. Twenty-four hours post plating, fresh media was supplied and cells were
incubated with either equal volume of sterile water (vehicle control) or ICA-1
(0.04µM to 0.1µM). Following the initial exposure to ICA-1, additional doses of
sterile water or ICA-1 were supplied every 24 hour during the three day
incubation period. In order to analyze the effect of ATM (aurothiomalate) on cell
viability, LA1-5s and BE(2)-C cells were treated with DPBS (vehicle control) or
ATM (0.01µM - 100µM). Cell viability was determined at 24, 48 and 72 hours.
Cell viability was quantified using a Trypan blue exclusion assay.
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8.17 Analysis of apoptosis
The first method used was DAPI staining. BE(2)-C cells were grown in
glass chamber slide (BD Bioscience) and treated with ICA-1 as in the cell
viability assay. Forty eight hours post-treatment, cells were washed three times
with cold 1x DPBS, fixed with 1:1 methanol and acetone (5 minutes at -20°C) and
washed again 3 times with 1x DPBS. Cell nuclei were visualized in mounting
medium containing DAPI (blue, Vector Laboratories, Inc) using a Nikon Eclipse
TE2000-U microscope. Pictures were captured by NIS-Elements F Version 2.10.
The second method used was TUNEL Assay. DNA fragmentation was
visualized by means of fluorescence staining using a TUNEL apoptosis detection
kit according to the manufactures instructions. BE(2)-C cells were grown and
treated with ICA-1 as explained for DAPI staining. At 48 hours, the cells were
fixed using 4% paraformaldehyde in 0.1 M NaH2PO4 , pH 7.4, followed by
incubation for 60 minutes in a reaction mixture composed of biotin-dUTP and
terminal deoxynucleotidyl transferase. The sample was then incubated with
fluorescein isothiocyanate-avidin (FITC-avidin) for 30 minutes. The positively
stained cells were observed and photographed for DAPI staining.
Finally, the apoptosis was determined by analysis of Caspase-3 and
PARP cleavage. BE(2)-C cells were cultured in 100 mm tissue culture flasks and
treated with ICA-1 as in the cell viability assay. Protein (200µg) was separated
by SDS-PAGE and immunoblotted.
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8.18 Preparation of cytoplasmic and nuclear extracts
Cells were washed twice with cold PBS and resuspended in hypotonic b
buffer. The buffer is comprised of 50 mM HEPES (pH 7.4), 10 mM KCl, 1 mM
EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM PMSF, 2.5 lg/m leupeptin, 0.15
U/ml aprotinin. The lysates were then centrifuged at 30 min 4000g for 30 min at
4 ˚C. The cytoplasmic fraction (supernatant) was separated and collected. The
nuclear fraction (pellet) was suspended in a Buffer containing 400 mM KCl and
0.5% Triton X-100. The lysates were then centrifuged at 14,000g for 30 min at
4˚C and the supernatant containing nuclear extracts was collected.
8.19 In-vitro kinase activity assay to analyze the phosphorylation of
endogenous Elk-1 by PKC-ι
PKC-ι (0.5μg) was immunoprecipitated from cell lysates of BE(2)-C
malignant neuroblastoma cells and T98G malignant glioma cells. And suspended
in 200μl of PKC kinase buffer [150] to test the ability of PKC-ι to phophorylate
Elk-1. The reaction was terminated after incubation for 10 min at 30°C by placing
the samples in ice and adding sample loading buffer. Samples were then
fractionated by SDS-PAGE and immunoblotted via Western Blot analysis.
8.20 In-vitro kinase activity assay to analyze whether PKC-ι directly
phosphorylates recombinant Elk-1
Recombinant active PKC-ι (0.5μg) and recombinant active Elk-1 (0.5μg)
were subjected to an in-vitro kinase activity assay in the presence and absence
of recombinant active ERK1. The phosphorylation of Elk-1 by ERK1 was used
as the positive control. The proteins were then separated by SDS-PAGE and
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Western blotted to determine the phosphorylation of Elk-1. Data represents N=2
independent experiments.
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